IP Verse

Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9) - EP2756004

EP2756004

REGENERON PHARMACEUTICALS
Application Number
EP12761864A
Filing Date
Sep 12, 2012
Status
Opposition Rejected
Apr 19, 2024
Grant Date
Dec 25, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP4252857B1
EP3506931B1
EP3889181B1

Bibliography

The patent EP2756004B1 was granted to Regeneron Pharmaceuticals on Dec 25, 2019 following the initial filing on Sep 12, 2012 under the application number EP12761864A . The current legal status of the patent is Opposition Rejected.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBBSep 25, 2020ADMISSIBLE
AMGENDec 27, 2019ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents